{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:31:11Z","timestamp":1783571471851,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.vaccine.2022.09.009","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T01:21:06Z","timestamp":1663118466000},"page":"6100-6106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity"],"prefix":"10.1016","volume":"40","author":[{"given":"Hidehiko","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Matsugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakika","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyo","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Miyazato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0001-7825","authenticated-orcid":false,"given":"Hirotaka","family":"Ebina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2022.09.009_b0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1128\/CMR.00040-16","article-title":"Human Parvoviruses","volume":"30","author":"Qiu","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2022.09.009_b0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/bdra.23588","article-title":"Parvovirus B19 infection during pregnancy and risks to the fetus","volume":"109","author":"Ornoy","year":"2017","journal-title":"Birth Defects Res"},{"key":"10.1016\/j.vaccine.2022.09.009_b0015","unstructured":"Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease."},{"issue":"2","key":"10.1016\/j.vaccine.2022.09.009_b0020","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/jvi.60.2.548-557.1986","article-title":"Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments","volume":"60","author":"Cotmore","year":"1986","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.09.009_b0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/v8030061","article-title":"The receptor-binding domain in the VP1u region of parvovirus B19","volume":"8","author":"Leisi","year":"2016","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.vaccine.2022.09.009_b0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/v8100265","article-title":"The VP1u receptor restricts parvovirus B19 Uptake to permissive Erythroid Cells","volume":"8","author":"Leisi","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2022.09.009_b0035","unstructured":"Enders M, Weidner A Fau - Enders G, Enders G. Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany."},{"key":"10.1016\/j.vaccine.2022.09.009_b0040","unstructured":"Vyse AJ, Andrews Nj Fau - Hesketh LM, Hesketh Lm Fau - Pebody R, Pebody R. The burden of parvovirus B19 infection in women of childbearing age in England and Wales."},{"issue":"3","key":"10.1016\/j.vaccine.2022.09.009_b0045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1128\/CMR.15.3.485-505.2002","article-title":"Human parvovirus B19","volume":"15","author":"Heegaard","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2022.09.009_b0050","unstructured":"Valeur-Jensen AK, Pedersen Cb Fau - Westergaard T, Westergaard T Fau - Jensen IP, Jensen Ip Fau - Lebech M, Lebech M Fau - Andersen PK, Andersen Pk Fau - Aaby P, et al. Risk factors for parvovirus B19 infection in pregnancy."},{"key":"10.1016\/j.vaccine.2022.09.009_b0055","unstructured":"Safiyanu MB, Akande AO, Babayo AA-OX, Umar J, Abdullahi IA-O. Serological detection of human parvovirus B19 infection and associated risk factors among pregnant women in Jigawa State, Nigeria."},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.009_b0060","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J Nanobiotechnology"},{"issue":"36","key":"10.1016\/j.vaccine.2022.09.009_b0065","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1016\/j.vaccine.2021.07.046","article-title":"Fusion of parvovirus B19 receptor-binding domain and pneumococcal surface protein A induces protective immunity against parvovirus B19 and Streptococcus pneumoniae","volume":"39","author":"Suzuki","year":"2021","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.09.009_b0070","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1086\/368382","article-title":"Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1","volume":"187","author":"Ballou","year":"2003","journal-title":"J Infect Dis"},{"issue":"43","key":"10.1016\/j.vaccine.2022.09.009_b0075","doi-asserted-by":"crossref","first-page":"7357","DOI":"10.1016\/j.vaccine.2011.07.080","article-title":"Safety and immunogenicity of a candidate parvovirus B19 vaccine","volume":"29","author":"Bernstein","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.09.009_b0080","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1534-5807(01)00031-4","article-title":"A viral phospholipase A2 is required for parvovirus infectivity","volume":"1","author":"Z\u00e1dori","year":"2001","journal-title":"Dev Cell"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.009_b0085","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.pharmtox.39.1.175","article-title":"Regulation and inhibition of phospholipase A2","volume":"39","author":"Balsinde","year":"1999","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.009_b0090","doi-asserted-by":"crossref","DOI":"10.1186\/1423-0127-16-13","article-title":"Effects of human parvovirus B19 VP1 unique region protein on macrophage responses","volume":"16","author":"Tzang","year":"2009","journal-title":"J Biomed Sci"},{"issue":"37","key":"10.1016\/j.vaccine.2022.09.009_b0095","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1016\/j.vaccine.2013.06.062","article-title":"Generation of a parvovirus B19 vaccine candidate","volume":"31","author":"Chandramouli","year":"2013","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2022.09.009_b0100","doi-asserted-by":"crossref","first-page":"11370","DOI":"10.1128\/JVI.01041-06","article-title":"Phospholipase A2 activity-dependent stimulation of Ca2+ entry by human parvovirus B19 capsid protein VP1","volume":"80","author":"Lupescu","year":"2006","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.09.009_b0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/(SICI)1097-0290(19960120)49:2<130::AID-BIT2>3.0.CO;2-R","article-title":"Production of parvovirus B19 vaccine in insect cells co-infected with double baculoviruses","volume":"49","author":"Tsao","year":"1996","journal-title":"Biotechnol Bioeng"},{"issue":"6","key":"10.1016\/j.vaccine.2022.09.009_b0110","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1172\/JCI115812","article-title":"Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface","volume":"89","author":"Rosenfeld","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2022.09.009_b0115","first-page":"140","article-title":"Multi Epitope Peptide Vaccine against Human Parvovirus B19 Using Immuno-Informatics Approaches","volume":"6","author":"Mohammed","year":"2018","journal-title":"Am J Microbiol Res"},{"key":"10.1016\/j.vaccine.2022.09.009_b0120","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1016\/j.vaccine.2003.06.003","article-title":"T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19","volume":"22","author":"Franssila","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.09.009_b0125","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1182\/blood-2003-05-1522","article-title":"Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry","volume":"102","author":"Weigel-Kelley","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.009_b0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jmv.20158","article-title":"Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis","volume":"74","author":"Kerr","year":"2004","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2022.09.009_b0135","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.12399","article-title":"Effect of N-terminal region of human parvovirus B19-VP1 unique region on cardiac injury in na\u00efve mice","volume":"24","author":"Hung","year":"2021","journal-title":"Mol Med Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2022.09.009_b0140","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1165\/ajrcmb.20.4.3420","article-title":"Both Erk and p38 kinases are necessary for cytokine gene transcription","volume":"20","author":"Carter","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.09.009_b0145","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/cmi.2010.24","article-title":"Understanding the development and function of T follicular helper cells","volume":"7","author":"Nurieva","year":"2010","journal-title":"Cell Mol Immunol"},{"issue":"25","key":"10.1016\/j.vaccine.2022.09.009_b0150","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2017.04.078","article-title":"Polysaccharide conjugate vaccine protein carriers as a \u201cneglected valency\u201d - Potential and limitations","volume":"35","author":"Br\u00f6ker","year":"2017","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.09.009_b0155","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1128\/jvi.67.6.3004-3009.1993","article-title":"Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions","volume":"67","author":"Saikawa","year":"1993","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.009_b0160","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0042-6822(95)80079-4","article-title":"Peptides derived from the unique region of B19 parvovirus minor capsid protein elicit neutralizing antibodies in rabbits","volume":"206","author":"Anderson","year":"1995","journal-title":"Virology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22011045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22011045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:19:40Z","timestamp":1759403980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22011045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":32,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0264410X22011045"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.09.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}